Drug Profile
Autologous chondrocyte implantation - Biosolutions
Alternative Names: CartiLife; CCP-ACILatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator MCTTBio
- Developer Biosolution
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cartilage disorders
Most Recent Events
- 28 Oct 2020 Phase-II clinical trials in Cartilage disorders in USA (Parenteral) (NCT04744402)
- 30 Apr 2020 Biosolutions plans a phase III trial for Cartilage disorders in South Korea (KCT0004966),
- 17 Jan 2018 Phase-II development in Cartilage disorders is ongoing in South Korea (Biosolution pipeline, January 2018)